Pipeline

Curexsys is currently pursuing the development of several programs in three indications. Programs in one indications are pursued non-exclusive with an industry partner. We focus on the generation of clearly defined, characterized and purified extracellular vesicles / exosomes from our proprietary iMSC lines derived from Evotec’s iPSC platform. While we will pursue some indications ourselves or together with a partner, our technology would also allow to explore the therapeutic and rejuvenating potential of exosomes in various other indications, which we offer for partnerships.

completed or ongoing
in preparation or planned for 12-30 mth.
expected to start within 24-36 mth.

Ophthalmology

Development

Preclinical

Phase 1

Phase 2

Phase 3

Indication: Sicca
#
Indication: Sjogren’s syndrome

Dermatology

Development

Preclinical

Phase 1

Phase 2

Phase 3

Indication: Atopic dermatitis
#
Indication: Wound healing
#
Indication: Sun burn
#

Skeletal diseases

Development

Preclinical

Phase 1

Phase 2

Phase 3

Indication: Osteoporosis / Bone fractures
#
Indication: Disc prolapse
#

Technology

Development

Preclinical

Phase 1

Phase 2

Phase 3

Indication: General anti-aging
Indication: Cosmaceuticals

Market